Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Cerilliant
Healthtrust
Citi
Novartis
Express Scripts
Merck
Chinese Patent Office
Dow

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202442

« Back to Dashboard

NDA 202442 describes LATANOPROST, which is a drug marketed by Akorn, Amring Pharms, Apotex Inc, Bausch And Lomb, Dr Reddys Labs Ltd, Fdc Ltd, Mylan, and Sandoz Inc, and is included in eight NDAs. It is available from thirteen suppliers. Additional details are available on the LATANOPROST profile page.

The generic ingredient in LATANOPROST is latanoprost. There are nineteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

Summary for 202442

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202442

Ingredient-typeProstaglandins

Suppliers and Packaging for NDA: 202442

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 202442 ANDA FDC Limited 55545-1010 55545-1010-1 1 BOTTLE, DROPPER in 1 CARTON (55545-1010-1) > 2.5 mL in 1 BOTTLE, DROPPER
LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 202442 ANDA Rising Pharmaceuticals, Inc. 64980-516 64980-516-25 1 BOTTLE, DROPPER in 1 CARTON (64980-516-25) > 2.5 mL in 1 BOTTLE, DROPPER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.005%
Approval Date:Apr 22, 2016TE:ATRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chubb
Cerilliant
Teva
Medtronic
AstraZeneca
Merck
Citi
Cipla
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot